Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to Biomimetics: Biomimicry
Chemistry A field that creates synthetic chemicals which act like biological molecules
Molecular biology The development of synthetic systems based on information from biological systems
Technology The formal study of biological processes and systems as a model for creating synthetic structures similar to those produced in nature
References in periodicals archive ?
Biomimetic scaling dictates that a robot need mimic the animal's biological characteristics only to the degree that those features support the concept being tested.
We are delighted to have Steve and Earl join the management team at BioMimetic," commented Samuel E.
BioMimetic will be mailing a proxy statement/prospectus for its stockholders and each will be filing other documents regarding the proposed transaction with the SEC.
With the closing of this financing, BioMimetic has now raised approximately $51 million in equity funding since inception in 2001.
50 per share upon the achievement of $70 million in trailing twelve month sales for all products contributed by BioMimetic.
With the expanded pipeline into broader orthopaedic opportunities, we believe that BioMimetic has a bright future.
Further, BioMimetic's actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with the marketing of BioMimetic's products, the approval process for and the commercialization of its product candidates, preclinical and clinical development activities, risks relating to potential securities claims, product liability claims, other litigation or claims or regulatory inquiries that have been and may be brought against BioMimetic and its officers and directors, regulatory oversight, and other risks detailed in BioMimetic's filings with the Securities and Exchange Commission.
Samuel Lynch, founder, president and CEO of BioMimetic Therapeutics.
Additionally, BioMimetic received regulatory approval in 2009 and 2011 to market the product in Canada and Australia, respectively and is awaiting an approvability decision in Europe, which is expected during the first half of 2012.
In November 2009, BioMimetic received regulatory approval to begin marketing Augment Bone Graft as an alternative to autograft in foot and ankle fusion indications in Canada.
All products developed by BioMimetic are based upon recombinant human platelet-derived growth factor (rhPDGF-BB) platform technology, which is a synthetic form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration.
Today's panel meeting represents a major milestone for the Company, and one that our investigators and BioMimetic team have worked tirelessly to achieve over the last several years," said Dr.